cas 131748-14-6|| where to buy 4-Chloro-2-(trifluoromethyl)pyridine

製品名:4-Chloro-2-(trifluoromethyl)pyridine

IUPAC Name:4-chloro-2-(trifluoromethyl)pyridine

包装単位	有効在庫	価格（USD）
CM120691-25g	in stock	ŔǕ
CM120691-100g	in stock	ƄźƄ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 131748-14-6 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:131748-14-6; 分子式:C6H3ClF3N; 融点:-; SMILESコード:FC(C1=NC=CC(Cl)=C1)(F)F; 密度:

: カタログ番号:CM120691; 分子量:181.54; 沸点:; MDL番号:MFCD07368047; 保管方法:

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Emraclidine; Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive allosteric modulator(PAM) in development for the treatment of schizophrenia.
We believe emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development.